The Chemotherapy Drug Shortage: An Unprecedented Crisis
XTalks
JUNE 16, 2023
Concerningly, the survey also revealed that only 40 percent of the surveyed NCCN cancer centers received any indication from manufacturers or suppliers about when carboplatin or cisplatin would be readily available again. Medicines for Europe said the supply issues were evidence of the damaging effects of European cost-containment measures.
Let's personalize your content